Last reviewed · How we verify
NCT05014191
Treatment Positioning in Vulvar Cancer Radiation Therapy
trial in Radiation Toxicity in 20 participants. Completed in 1 January 2025.
1 January 2025
Quick facts
| Lead sponsor | King Hussein Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 July 2020 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across Jordan |
Conditions studied
- Radiation Toxicity — all drugs for Radiation Toxicity →
Sponsor
King Hussein Cancer Center — full company profile →
Who can join
Adults 18 to 80, female only, with Radiation Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study investigators will conduct a prospective study on patients with non-metastatic vulvar cancer who will receive radiation treatment using Volumetric Arc Therapy (VMAT) modality with curative intent. Our aim is to compare straight-leg versus frog-leg position in terms of RTOG acute skin toxicity. Also, the study investigators will evaluate if positioning has an impact on the total treatment time and deviation on Cone Beam CT (CBCT) that might warrant re-simulation and consequently re-planning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05014191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiation Toxicity
Currently open trials in the same condition.
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
- NCT06311968 — The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor · Phase 2 · recruiting
- NCT05530655 — A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy · EARLY_PHASE1 · recruiting
- NCT06215495 — A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial · NA · recruiting
- NCT06033183 — Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology · NA · recruiting
Other King Hussein Cancer Center trials
Trials by the same sponsor.
- NCT07271121 — Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL · Phase 2 · recruiting
- NCT06689358 — Thoracic Paravertebral Block for Postoperative Pain Management After VATS · NA · completed
- NCT04374903 — Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients · NA · withdrawn
- NCT04920513 — Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for · completed
- NCT04920656 — Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05014191 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King Hussein Cancer Center
- Last refreshed: 12 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05014191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing